Sv2a protein levels in the kainic acid epilepsy rat model during the acute phase

Abstract

Introduction The Kaïnic Acid model (KA) is one of the most validated models of temporal lobe epilepsy (TLE) (Lévesque et al.,2016). Its administration induces status epilepticus (SE), characterized by an extensive neuronal damage in limbic structures (Sperk et al.,1983). Post-mortem studies, such as the epilepsy model presented in (Wang et al., 2014), show a reduction of SV2A protein levels during the chronic phase, however, no data have been reported during the acute phase (0-48h after KA injection).. The present pilot study is undertaken to evaluate in vivo, with the specific radiotracer [18F]UCB-H (Bretin et al., 2015; Warnock et al., 2014), the SV2A expression 24h after a SE produced by KA administration. Methods Two Sprague-Dawley rats were scanned at two different times: baseline, and 24h after three systemic injections of 5mg/kg KA. The scanning process consisted of a first scan with microPET (Focus 120), during 1 hour, using [18F]UCB-H (41 ± 5 MBq IV tail vein). This is followed by MRI (9.4T Agilent, anatomical T2). A coregistration was performed with PMOD 3.6 software. Data were expressed as SUV and AUC were calculated for the different brain regions. Results [18F]UCB-H microPET images exhibited a small reduction (around 10%) in SV2A brain levels after KA injections compared to the baseline, marked in thalamus, hippocampus and amygdale. MRI images obtained 24h after KA injections are in accordance with previous histological studies, revealing inflammatory edema, tissue necrosis and increased ventricle volume (Sperk et al.,1983). Conclusions These preliminary results obtained in KA treated rats show that [18F]UCB-H is able to detect alterations in SV2A levels in relevant regions for epilepsy. This radiotracer emerges as a valuable tool to follow in vivo SV2A through longitudinal studies. KA model in rats deserves as a tool for the study of epilepsy, exhibiting the same features than the human disease. References [1] Lévesque et al., J Neurosci Methods, 2016 [2] Sperk et al., Neuroscience, 1983 [3] Wang et al., J Mol Neurosci., 2014 [4] Bretin et al., Molecular Imaging and Biology, 2015 [5] Warnock et al., J Nucl Med., 2014 [5] Van Nieuwenhuyse et al., Brain Research, 2015 [6] Hellier et al., Epilepsy Res., 1998The SV2A protein projec